<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20251228068472N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-02-14</date_registration>
      <primary_sponsor>Arak University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of multidural slit and dural flap in the evacuation of acute subdural hematoma of the brain</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation and comparison of the results of acute subdural hematoma evacuation by two methods of multidural stabs versus open dural flap</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-02-14</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>94</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/88907</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: To allocate the samples, a block randomization method with blocks of 8 will be used. Thus, using the block random number generation software, a randomization sequence will be generated in proportion to the required sample size for the two groups. Initially, all the cases in which the 2 letters A, B can be arranged together in a block of 8 are generated. Then, a block is randomly selected from the blocks by placing them, and the arrangement pattern in that block will be used to allocate the participants. Then, this block is placed in the main container and another block will be selected again. All of this will be done with a software called Sealed Envelope. Using this method, concealment will also be observed. The concept of concealment is to make the allocation of individuals to groups unpredictable. In fact, the researcher will not be able to predict which group the next person will be placed in, Blinding description: This study will be double-blind, for this purpose, patients and outcome assessors are blinded. Patients who are unaware of the type of surgery due to reduced level of consciousness and the type of technique performed will be unaware of the surgery. On the other hand, the surgery will be performed by a neurosurgeon and the follow-up and evaluation of patients will be performed by the intern responsible for the project. Therefore, the outcome assessor, who is the intern responsible for the project, will be unaware of the patient grouping and will evaluate patients based on the case number and information received from the attending (neurosurgeon).</study_design>
      <phase>3</phase>
      <hc_freetext>Subdural Hematoma.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: 94 patients with subdural hematoma will undergo surgery using the Durmer flap technique. In this method, a decompression craniectomy is performed by removing parts of the frontal, temporal, parietal, and occipital bones, resulting in the creation of a large bone flap (diameter &gt; 12 cm). The dura is then opened in a C-shape towards the base of the skull to drain the hematoma and achieve hemostasis. (Complete duraplasty is performed with the temporalis fascia or pericranium). The advantage of this method is that it immediately reduces intracranial pressure. Intervention 2: Intervention group: Intervention group 2: 94 patients with subdural hematoma will undergo surgery using the multidural slit technique. This is a decompression procedure for acute subdural hematoma in the presence of severe cerebral edema and midline shift to preserve the arachnoid tissue, pia, brain tissue, and its vessels by opening the dura. In this surgical procedure, several linear incisions of 5-8 mm in length are made with a No. 11 knife, in horizontal lines, parallel to the vessels, and 2-2.5 cm apart. Caution is that the tip of the knife should not penetrate more than 0.5 to 1.0 mm in depth. Normal saline is continuously used to flush the dura from blood and clots, and a soft silastic catheter is inserted to remove clots stuck on the brain surface.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No more information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Samar Kamalifar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Payambar Azam Complex, Sardasht Town</address>
        <city>Arak</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3848176341</zip>
        <telephone>+98 86 3417 3505</telephone>
        <email>samarkamalifar@gmail.com</email>
        <affiliation>Arak University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Samar Kamalifar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Payambar Azam Complex, Sardasht Town</address>
        <city>Arak</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3848176341</zip>
        <telephone>+98 86 3417 3505</telephone>
        <email>samarkamalifar@gmail.com</email>
        <affiliation>Arak University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age 18 to 60 years
Patients with acute subdural hematoma requiring surgery without other associated bleeding</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Underlying coagulation disorder
Brain tumor</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>S06.5</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Traumatic subdural hemorrhage</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: 94 patients with subdural hematoma will undergo surgery using the Durmer flap technique. In this method, a decompression craniectomy is performed by removing parts of the frontal, temporal, parietal, and occipital bones, resulting in the creation of a large bone flap (diameter &gt; 12 cm). The dura is then opened in a C-shape towards the base of the skull to drain the hematoma and achieve hemostasis. (Complete duraplasty is performed with the temporalis fascia or pericranium). The advantage of this method is that it immediately reduces intracranial pressure.</i_keyword>
      <i_keyword>Intervention group: Intervention group 2: 94 patients with subdural hematoma will undergo surgery using the multidural slit technique. This is a decompression procedure for acute subdural hematoma in the presence of severe cerebral edema and midline shift to preserve the arachnoid tissue, pia, brain tissue, and its vessels by opening the dura. In this surgical procedure, several linear incisions of 5-8 mm in length are made with a No. 11 knife, in horizontal lines, parallel to the vessels, and 2-2.5 cm apart. Caution is that the tip of the knife should not penetrate more than 0.5 to 1.0 mm in depth. Normal saline is continuously used to flush the dura from blood and clots, and a soft silastic catheter is inserted to remove clots stuck on the brain surface.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Level of consciousness. Timepoint: Before and after the intervention. Method of measurement: Glasgow Coma Scale.</prim_outcome>
      <prim_outcome>Disease outcome based on Glasgow Outcome Scale. Timepoint: Before and after the intervention. Method of measurement: Glasgow Outcome Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Arak University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-05-19</approval_date>
        <contact_name>Ethics committee of Arak University of Medical Sciences</contact_name>
        <contact_address>Payambar Azam Complex, Sardasht Town Arak Markazi Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
